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Introduction: Relationships of parity with breast cancer risk are complex. Parity is associated with decreased risk of
postmenopausal hormone receptor–positive breast tumors, but may increase risk for basal-like breast cancers and
early-onset tumors. Characterizing parity-related gene expression patterns in normal breast and breast tumor tissues
may improve understanding of the biological mechanisms underlying this complex pattern of risk.
Methods: We developed a parity signature by analyzing microRNA microarray data from 130 reduction
mammoplasty (RM) patients (54 nulliparous and 76 parous). This parity signature, together with published parity
signatures, was evaluated in gene expression data from 150 paired tumors and adjacent benign breast tissues from
the Polish Breast Cancer Study, both overall and by tumor estrogen receptor (ER) status.
Results: We identified 251 genes significantly upregulated by parity status in RM patients (parous versus nulliparous;
false discovery rate = 0.008), including genes in immune, inflammation and wound response pathways. This parity
signature was significantly enriched in normal and tumor tissues of parous breast cancer patients, specifically in
ER-positive tumors.
Conclusions: Our data corroborate epidemiologic data, suggesting that the etiology and pathogenesis of breast
cancers vary by ER status, which may have implications for developing prevention strategies for these tumors.Introduction
Parity is associated with lower lifetime breast cancer
risk, with changes in differentiation of breast epithelium
proposed as a protective mechanism [1]. However, the
relationship between parity and breast cancer is complex,
and it depends on age, timing of the pregnancy and tumor
subtype. Despite decreased lifetime risk, parity has been
suggested to increase breast cancer risk transiently follow-
ing pregnancy [2]. Other analyses suggest a qualitative age
interaction, with parity increasing risk early in life and de-
creasing it in older women [3]. The results of mechanistic
studies suggest that increases in hormone levels during
pregnancy or in inflammatory microenvironments present
during postpartum involution [4,5] may increase breast* Correspondence: rotunnom@mail.nih.gov
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unless otherwise stated.cancer risk in the years following a birth. However, beyond
these temporal trends, there are other nuances in parity–
breast cancer associations, with some data suggesting that
factors such as age at first birth [2,6], tumor estrogen re-
ceptor (ER) status [7-9], menopausal status or age at diag-
nosis [3] and breastfeeding patterns [10,11] may modify
these associations.
Unraveling the complexity of parity and breast cancer
risk requires a better understanding of molecular changes
associated with parity, together with the recognition of the
heterogeneity of breast tumors. In recent studies, some re-
searchers have described parity-induced molecular signa-
tures based on their genome-wide expression profiling of
normal breast tissues obtained from healthy women
[12-14], which provides new insights into the molecular
basis of parity-associated risk protection through alteration
of transcription regulation, centrosome organization, RNA
splicing, cell-cycle control, adhesion and differentiation.
Meanwhile, evaluation of molecular heterogeneity of tu-
mors has led to dramatic changes in our conceptualization
of breast cancer, which is now widely recognized asal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Rotunno et al. Breast Cancer Research 2014, 16:R74 Page 2 of 12
http://breast-cancer-research.com/content/16/4/R74representing at least five molecular subtypes with distinct
clinicopathological characteristics and risk factor profiles
[9,15-17]. This tumor heterogeneity is particularly import-
ant in relation to parity because parity and early age at
first full-term birth are associated with reduced risk for
ER-positive (ER+) or and (ER + or PR+) breast tumors,
but they do not seem to reduce, or they may even in-
crease, lifetime risk for ER-negative (ER−), particularly
triple-negative (ER − and PR − and HER2−) breast tumors
[8,18-23]. These findings suggest that parity-related fac-
tors may influence breast cancer risk through different
molecular pathways in ER + and ER − tumors.
In this study, we identified a novel parity-related signa-
ture using gene expression profiling data obtained from
reduction mammoplasty (RM) specimens. We then tested
this parity signature, as well as signatures from previously
published studies of normal tissue [12-14,24], in paired
tumor and normal tissues collected from breast cancer pa-
tients in the Polish Breast Cancer Study (PBCS) [25]. We
demonstrate that parity-related molecular processes iden-
tified in normal breast tissues of cancer-free women were
preserved in normal breast tissues from cancer patients.
Furthermore, even ER + tumor tissues persisted in ex-
pressing some parity-associated gene expression patterns,
suggesting that tumor biology may reflect patient expo-
sures that predate carcinogenesis.
Methods
Identification of parity-related gene expression signature
Study population and sample handling
Samples were obtained from normal breast tissue of
women ages 14 to 70 years who had undergone RM sur-
gery at Baystate Medical Center (Springfield, MA, USA)
and whose tissues were banked at the Pioneer Valley Life
Sciences Institute (PVLSI) between 2007 and 2010 [26,27].
Specimens were excluded if pathologic assessment of
patient-matched, paraffin-embedded tissues demonstrated
benign breast disease or neoplastic lesions. Demographic
and reproductive information was collected by telephone
interview following surgery. The present study was limited
to the subjects with complete data on parity, as well as
available fresh-frozen tissues so that we could perform
gene-profiling analysis, including 54 nulliparous and 76
parous women. The tissue processing, RNA isolation,
microarray profiling and preprocessing of gene expression
data have been described previously in detail [26,27]. All
gene expression data are publicly available through the
Gene Expression Omnibus [GSE:16113, GSE:33526].
Data analysis
Significance Analysis of Microarrays (SAM) was used to
detect differentially expressed genes (with the nulliparous
group as the reference) using false discovery rate (FDR <
0.01) to control type I errors due to multiple testing [28].This method is preferable to fold change–based thresholds
methods because it accounts for both variation and
multiple testing in gene selection [28]. Genes that were
significantly differentially expressed by parity were clus-
tered across all samples using average linkage hierarchical
cluster analysis, and results were visualized using Java
TreeView software [29]. Ontology classification and path-
way analyses were performed on the identified genes using
GoMiner software [30].
Expression of identified parity signature in tumor and
paired adjacent normal tissues
Study population and sample handling
The PBCS is a population-based case–control study con-
ducted in two major cities in Poland (Warsaw and Łódź)
from 2000 to 2003 [25]. The PBCS patients were women
ages 20 to 74 years with newly diagnosed, pathologically
confirmed in situ or invasive breast carcinoma identified
using a rapid identification system organized at five partici-
pating hospitals and via cancer registries. Fresh tissues
from invasive tumors, cancer-adjacent breast tissues and
mammary fat tissues were collected from a subset of 227
patients at the time of breast surgery and snap-frozen in
liquid nitrogen. Compared to other PBCS patients, the
subset of 227 patients had significantly larger and node-
positive tumors (Additional file 1: Table S1). A set of 150
paired tumor and cancer-adjacent benign breast samples,
which were oversampled for basal-like and luminal cancers
and associated tissues, were included in the present study.
These samples were selected based on in vitro evidence
that microenvironments associated with luminal and basal
breast cancer subtypes differ [31]. Cancer-adjacent breast
tissues used in this study were <2 cm from the tumor edge.
Information on clinicopathological, demographic and an-
thropometric factors was collected from medical records
and in-person interviews. Procedures for construction of
tumor tissue microarrays, immunohistochemical staining
and scoring of key markers, including ER, have been de-
scribed in detail elsewhere [32,33].
Two-color Agilent 4 × 44K whole-genome arrays (Agilent
Technologies, Santa Clara, CA, USA) were used to evaluate
gene expression in cancer-adjacent normal tissues. The de-
tails regarding tissue processing, RNA isolation, microarray
profiling and preprocessing of gene expression data have
been described previously [34]. Illumina HumanRef-8 v2
Expression BeadChip arrays (Illumina, San Diego, CA, USA)
were used to evaluate gene expression in tumor tissues.
In brief, 250 ng of input RNA was amplified and la-
beled using the Illumina TotalPrep RNA amplification
kit (Ambion/Life Technologies, Austin, TX, USA) accord-
ing to the manufacturer’s recommended protocol. The
biotin-labeled cRNAs were quantitated using Quant-iT
RiboGreen RNA quantitation reagent (Molecular Probes/
Invitrogen, Eugene, OR, USA), and 750 ng was hybridized
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rays (Illumina). Quality checks and data normalization were
conducted using standard Illumina preprocessing methods.
In particular, the variance stabilization transformation was
used, followed by quantile normalization. The number of
significant (P < 0.05) detection calls was similar across ar-
rays. All gene expression data are publicly available through
the Gene Expression Omnibus [GSE: 49175].
Data analysis
We used two methods, gene set enrichment analysis (GSEA)
[35] and Creighton correlation [36], to test whether the
parity signatures from healthy women were associated
with parity status in PBCS based on their expression
values for the parity-related genes. Both parous and nul-
liparous women were included in these analyses. GSEA
was used to test the enrichment of the parity signature
identified in RM patient tissues from PVLSI (PVLSI signa-
ture) among parous compared to nulliparous PBCS
women. GSEA reveals patterns of gene expression from a
given gene set (RM-derived parity signature in this study),
even when single-gene analysis reveals very few overlap-
ping, statistically significant genes. A running enrichment
score (ES) is calculated by walking down the entire list of
probes in the PBCS gene expression array ordered by
t-test coefficients divided by the standard error values
from the parous–nulliparous comparison. This running-
sum statistic increases when a given probe is in the PVLSI
gene set and decreases otherwise, with the magnitude of
increment depending on the strength of the correlation
between the probe and the parous–nulliparous compari-
son in the PBCS data set. We defined the ES as the max-
imum deviation of the running ES from zero encountered
in the random walk. It reflects the degree to which the
gene set was overrepresented at the extremes of the entire
ranked probe list. Distributions of ES values were created
through a permutation procedure and used to calculate
the statistical significance of the observed ES values. A
permutation-based family-wise error rate (FWER) ≤ 15%
was considered as significant. The Creighton correlation
method has been described previously [34]. Briefly, stand-
ard vectors corresponding to all genes in the parity signa-
ture were constructed, with 1 and −1 assigned to genes
with fold changes greater and smaller than the median,
respectively. A Pearson correlation coefficient was calcu-
lated for this standard vector compared to the vector
of median centered gene expression for each patient.
Patients were classified as positive for parity signature
if the Pearson correlation coefficient was greater than
zero and as negative if the coefficient was less than zero.
Associations of parity signatures with parity status of sub-
jects (nulliparous versus parous) were assessed using un-
conditional logistic regression by estimating odds ratios
(ORs) with 95% confidence intervals (CIs) and by the χ2test (or Fisher’s exact test when expected cell count was
less than five) for P-values with a threshold for signifi-
cance equal to 0.05.
The GSEA and Creighton methods are analytically and
conceptually different and were used to test two related
but distinct questions. We used GSEA to test whether
there was a significant subgroup of the genes in the parity
signature that was differentially expressed in parous versus
nulliparous cancer patients. The Creighton method was
used to test whether the parity signature as a whole could
predict parity status of cancer patients. Sensitivity ana-
lyses were performed to assess heterogeneity of gene
expression among cancer patients. GSEAs were strati-
fied by age at first birth (≤ 25 years versus > 25 years
prior), interval since most recent birth (< 10 years
versus ≥ 10 years) and menopausal status.
Comparison with previously published parity signatures
We assessed two previously published data sets designed to
identify gene expression signatures by parity in normal hu-
man tissues: (1) a candidate gene study by Asztalos et al.
[24], who examined the expression of 64 candidate genes
using real-time PCR in mammoplasty benign biopsy spec-
imens from 13 nulliparous and 11 parous age-matched
premenopausal women from the University of Illinois at
Chicago Hospital (UICH); and (2) a genome-wide expres-
sion data set (GeneChip Human Genome U133 Plus 2.0
oligonucleotide array; Affymetrix, Santa Clara, CA, USA)
based on normal breast samples from 67 parous and 40
nonparous postmenopausal healthy volunteers recruited
at the Sunderby Hospital in Luleå, Sweden (SHL).
The SHL expression profiling data set was published
in three independent papers (Belitskaya-Lévy et al.
[12], Russo et al. [13] and Peri et al. [14]). Because these
three research groups used similar statistical methods and
generated similar parity signatures, we focused our com-
parisons on the signature published first, in the paper by
Belitskaya-Lévy et al. Parity-related genes from the two
signatures (UICH and SHL) are listed in Additional file 1:
Table S2. The associations between parity and gene ex-
pression of UICH and SHL parity signatures were evalu-
ated in normal tissues from the PVLSI study and in tumor
and paired cancer-adjacent normal tissues from the PBCS,
using the Creighton correlation and GSEA as described
above. Data analyses were performed using R (version
3.0.0) [37].
The study protocols were approved by the institutional
review boards (IRBs) of each participating institution,
and written informed consent was obtained from every
participant. The IRB at Baystate Medical Center ap-
proved RM sample procurement for the PVLSI women,
and the IRB at the University of North Carolina ap-
proved the microarrays and statistical analyses of these
samples. For the PBCS cases, the collection of breast
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presented here were covered by the protocol of the Breast,
Ovarian and Endometrial Cancer Case–Control Study
in Poland, which was approved by the National Cancer
Institute Special Studies IRB (OH99CN040).
Results
Comparison of sample sets
There were some differences in subject characteristics,
source of breast tissues and expression profiling plat-
forms across different studies (Table 1). Although the
fresh whole-breast tissue analyzed in PVLSI RMs, PBCS
cancer-adjacent normal tissues and SHL core biopsies
consisted of both stromal and epithelial tissues, epithe-
lial cells were microdissected in the UICH sample and
comprised the dominant cell type in tumors from the
PBCS. As is typical for women undergoing RM, PVLSI
and UICH patients tended to be more obese and youn-
ger (therefore premenopausal) than the SHL and PBCS
patients. The PVLSI patients were also younger (mean
age = 37 years) and more likely to have had a most re-
cent birth < 10 years prior (68%) than were breast cancer
patients in the PBCS group (3%).
Discovery of parity signature in PVLSI mammoplasty
specimens
By gene expression profiling analysis of PVLSI samples, we
identified 251 upregulated genes (and no downregulated
genes) associated with parity (with nulliparous women
used as a reference; FDR = 0.008). Gene names, fold
changes, FDRs and P-values are listed in Additional file 1:
Table S3. The prediction of parity status based on theTable 1 Differences in study design, experimental approache
Study demographics PVLSI SHLb [12] U
Cancer status Cancer-free Cancer-free C
Tissue source Fresh whole tissue Core needle biopsies M
Tissue enrichment Stroma Epithelial and stromal Ep
Gene expression platform Agilent 4 × 44K GeneChip U133Plus 2.0 R
Samples
Total 130 107 2
ER+, n (%) N/A N/A N
Parous, n (%) 76 (58%) 67 (63%) 1
Premenopausal, n (%) 84 (65%) 0 (0%) 2
Mean age (±SD), yr 37 (13) 60 (5) 2
Mean BMI (±SD) 30c (6) 25 (4) –
a%, Percentage for categorical variables; BMI, Body mass index; FFPE, Formalin-fixed, p
Study; PVLSI, Samples obtained from normal breast tissue of 130 women who underw
MA, USA, and banked at the Pioneer Valley Life Sciences Institute; SD, Standard deviati
healthy volunteers recruited at the Sunderby Hospital in Luleå, Sweden; UICH, Mammo
University of Illinois at Chicago Hospital. bFrom previously published, parity-rela
(43%) missing BMI values in the PVLSI group.clustering with this parity signature (Figure 1) showed
fair agreement with actual phenotype, with greater accuracy
seen among parous women (accuracy = 76%) than in nul-
liparous women (accuracy = 54%). We examined whether
the parity-associated gene expression signature varied by
age at first birth (≤ 25 years versus > 25 years), interval
between most recent birth and tissue collection (< 10
versus ≥ 10 years) and menopausal status in the RM data
set. The predictive accuracy of the identified parity signa-
ture among parous women did not differ significantly by
age at first birth (70% for ≤ 25 years versus 57% for > 25
years; P = 0.28), interval since most recent birth (60%
for <10 years versus 75% for ≥ 10 years; P = 0.19) or meno-
pausal status (62% for premenopausal versus 61% for post-
menopausal women; P = 0.92).
Pathway analysis suggested that significant genes were
associated with immune, inflammation and wound re-
sponses. The top ten significant Gene Ontology database
biological processes are shown in Table 2. A complete
list is available in Additional file 1: Table S4.
Assessment of three parity signatures in mammoplasty
samples, cancer-adjacent tissues and cancer tissues
We assessed the enrichment of the three parity signa-
tures (PVLSI, SHL and UICH) in three different tissue
sample sets: (1) mammoplasty tissues from PVLSI; (2)
cancer-adjacent, histologically normal tissue from PBCS
participants with invasive breast cancer; and (3) paired
tumor tissues from the same PBCS women. The results
of this analysis are shown in Table 3.
Gene expression of the identified PVLSI parity signature
was strongly enriched by parity in its PVLSI training set ass and sample characteristicsa
ICHb [24] PBCS cancer-adjacent
normal tissue
PBCS tumor tissue
ancer-free Breast cancer Breast cancer
icrodissected FFPE tissue Fresh whole tissue Fresh whole tissue
ithelial Stroma Epithelial
T-PCR of 64 genes Agilent 4 × 44K Illumina
4 150
/A 117 (78%)
1 (46%) 119 (79%)
4 (100%) 41 (27%)
9 (6) 56 (10)
28 (5)
araffin-embedded; N/A, Not applicable; PBCS, Polish Breast Cancer Case–Control
ent reduction mammoplasty surgery at Baystate Medical Center in Springfield,
on for continuous variables; SHL, Normal breast samples from 107 postmenopausal
plasty benign biopsy specimens from 24 premenopausal women from the
ted gene expression signatures in healthy women [12,24]. cThere were 56
Figure 1 Unsupervised HeatMap cluster analysis. The heatmap illustrates our analysis of the 251 parity-related gene expression profiles of
normal breast samples from cancer-free women who had undergone reduction mammoplasty surgery at Baystate Medical Center (Springfield,
MA, USA) and whose tissue is banked at the Pioneer Valley Life Sciences Institute.
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3.95, P-valueCreighton = 0.0002). Considering all invasive
cancer patients (ER + and ER − cases combined), GSEA
analyses showed that, though enrichment was weaker than
among normal RM tissues, there was a significant enrich-
ment of the PVLSI parity signature in tumor-adjacent nor-
mal tissues (ESGSEA = 0.52, FWERGSEA = 5%). The parity
signature was further diluted and was then no longer sig-
nificant in tumor tissues (ESGSEA = 0.47, FWERGSEA =
18%). The results obtained using the Creighton correlation
method were consistent with those based on GSEA.
The UICH signature reported by Asztalos et al. [24] was
significantly positively correlated with parity in normal
PVLSI tissues on the basis of both GSEA and Creighton
analysis (ESGSEA = 0.71, FWERGSEA = 3%, ORCreighton = 2.4,
P-valueCreighton = 0.01). Similar to our PVLSI signature,
the UICH signature also showed a gradient loss of enrich-
ment from normal samples to tumor samples on the basis
of GSEA results, but not in the Creighton analysis, which
is based on a dichotomous classification.We did not observe any significant positive association
or trend between the SHL signature and parity in the
three examined tissue data sets.
Evaluation of parity signatures in benign cancer adjacent
and cancer tissues by estrogen receptor status
To study the distinct effect of parity by breast cancer
subtype, we evaluated the enrichment of parity signa-
tures when PBCS samples were stratified by tumor ER
status. As shown in Table 4, by GSEA, we observed that
our PVLSI signature was significantly enriched by parity
in ER + patients (cancer-adjacent normal: ESGSEA = 0.45,
FWERGSEA = 12%; tumor: ESGSEA = 0.50, FWERGSEA =
15%), but not among ER − patients (cancer-adjacent nor-
mal: ESGSEA = 0.37, FWERGSEA = 21%; tumor: ESGSEA =
0.31, FWERGSEA = 44%). Consistently, the results of the
Creighton analysis showed opposite associations of parity
with our PVLSI parity signature by tumor ER status in
both cancer-adjacent normal tissues (ER+: ORCreighton =
1.53; ER−: ORCreighton = 0.44) and tumor tissues (ER+:
Table 2 Top ten Gene Ontology database biological processes enriched by the 251 genes significantly upregulated in
normal breast samples of parous compared to nulliparous cancer-free PVLSI patientsa
GO category Gene names Total Up P-value FDR
[GO: 0002376] Immune
system process
KLHL6, HCLS1, LAT2, CD93, SLC7A7, DOK2, NCF4, PTPRC, VNN1, CD38, MAFB, CCL2,
ITK, ATP6V0A2, HCK, BLNK, TBX21, FCGR2B, FYB, BPGM, SCIN, CLEC4A, CD244, CD247,
TFEB, SNCA, CD48, TNFSF13B, IL6R, TLR3, CDKN2A, P2RX7, SYK, LCP1, C3AR1, ENPP3,
ANXA3, VAV1, LCP2, NDFIP1, CD14, TLR1, CD83, CSF1, TLR7, ITGAM, BST1, HLA-DMA,
CYBB, EPB42, PRG4, NCF1, WAS, SIX1, TLR6, CCR1, IL1R2, EDA, ITGB2, NCF2, CD28, CCL3
1,040 62 5.3E-19 < 0.001
[GO: 0006955] Immune
response
KLHL6, ENPP3, ANXA3, LAT2, LCP2, NDFIP1, NCF4, PTPRC, CD14, VNN1, CD38, TLR1,
CD83, CCL2, TLR7, ITK, ATP6V0A2, BLNK, TBX21, FCGR2B, FYB, BST1, CLEC4A, HLA-DMA,
CYBB, PRG4, CD247, NCF1, TFEB, SNCA, WAS, TNFSF13B, IL6R, TLR3, TLR6, CCR1, IL1R2,
EDA, ITGB2, SYK, P2RX7, NCF2, LCP1, CD28, CCL3, C3AR1
611 46 8.9E-18 < 0.001
[GO: 0006952] Defense
response
RNASE6, ANXA3, ADORA3, C1ORF38, ESR2, NDFIP1, PTPRC, CD14, VNN1, NLRC4, TLR1,
CD83, CCL2, TLR7, ITK, HCK, BLNK, NOX4, HRH1, CLEC4A, CYBB, CD247, NCF1, SNCA,
WAS, CD48, IL6R, LILRB3, TLR3, ALOX5AP, TLR6, AIF1, CCR1, ITGB2, P2RX7, LILRA3, NCF2,
CD28, CCL3, C3AR1
578 40 3.1E-14 < 0.001
[GO: 0045321] Leukocyte
activation
ANXA3, VAV1, LAT2, CD93, LCP2, NDFIP1, PTPRC, VNN1, TLR1, CD38, CD83, CSF1, TLR7,
BLNK, ITGAM, TBX21, HLA-DMA, CD247, SNCA, WAS, CD48, TNFSF13B, TLR3, CDKN2A,
TLR6, P2RX7, SYK, LCP1, CD28
336 29 7.5E-13 < 0.001
[GO: 0006954] Inflammatory
response
CYBB, ADORA3, C1ORF38, NDFIP1, CD14, IL6R, VNN1, NLRC4, TLR1, TLR3, ALOX5AP,
CCL2, TLR7, AIF1, TLR6, CCR1, ITGB2, BLNK, P2RX7, NOX4, HRH1, C3AR1, CCL3
265 23 1.9E-10 < 0.001
[GO: 0002682] Regulation
of immune system process
KLHL6, VAV1, LAT2, LCP2, NDFIP1, PTPRC, VNN1, CD38, CD83, MAFB, CSF1, TLR7, ITK,
HCK, TBX21, FCGR2B, FYB, SCIN, HLA-DMA, CD247, SNCA, TNFSF13B, WAS, IL6R, TLR3,
CDKN2A, TLR6, ITGB2, SYK, P2RX7, CD28, C3AR1
513 32 2.5E-10 < 0.001
[GO: 0002274] Myeloid
leukocyte activation
TLR1, TLR3, ANXA3, CSF1, LAT2, CD93, TLR7, TLR6, LCP2, SYK, SNCA, CD48 63 12 6.9E-10 < 0.001
[GO: 0009611] Response
to wounding
VAV1, IL10RA, SLC7A7, ADORA3, C1ORF38, LCP2, DOK2, NDFIP1, CD14, GATM, VNN1,
TLR1, NLRC4, CCL2, TLR7, BLNK, ITGAM, NOX4, HRH1, CYBB, CD244, WAS, CD48, IL6R,
TLR3, ALOX5AP, TLR6, AIF1, CCR1, ITGB2, SYK, P2RX7, LAMP2, PIK3CG, CCL3, C3AR1
671 36 1.1E-09 < 0.001
[GO: 0001775] Cell
activation
ANXA3, VAV1, LAT2, CD93, LCP2, NDFIP1, PTPRC, VNN1, CD38, TLR1, CD83, CSF1, TLR7,
BLNK, ITGAM, TBX21, HLA-DMA, CD247, SNCA, WAS, CD48, TNFSF13B, TLR3, CDKN2A,
TLR6, P2RX7, SYK, LAMP2, LCP1, CD28, PIK3CG
520 31 1.5E-09 < 0.001
[GO: 0050896] Response
to stimulus
HCLS1, KLHL6, FPR3, ANG, LAT2, IL10RA, SLC7A7, CACNA2D4, C1ORF38, PTGIS, DOK2,
NCF4, PTPRC, VNN1, PTPRO, CD38, NLRC4, FGF1, CCL2, ITK, ATP6V0A2, HCK, PTGS1,
BLNK, TBX21, NOX4, HRH1, FCGR2B, FYB, CLEC4A, HTR2B, CD244, CD247, TFEB, SNCA,
TNFSF13B, CD48, IL6R, LILRB3, TLR3, ALOX5AP, CDKN2A, AIF1, SYK, P2RX7, LILRA3, LCP1,
CRY1, LAMP2, C3AR1, ENPP3, ANXA3, RNASE6, VAV1, ADORA3, LCP2, ESR2, NDFIP1,
CD14, GATM, DYNLRB1, TLR1, CD83, TBXAS1, KCNQ1, CYP4V2, C20ORF39, HSPA6, TLR7,
CYB5R4, MAOB, ITGAM, ATP6V1F, BST1, HLA-DMA, CYBB, PRG4, NCF1, WAS, ABLIM2,
GDF10, TLR6, CCR1, CNGA1, AGPS, IL1R2, EDA, ITGB2, NCF2, CD28, TFEC, PIK3CG, CCL3
3,121 93 2.0E-09 < 0.001
aFDR, False discovery rate; GO, Gene Ontology; PVLSI, Samples obtained from normal breast tissue of 130 women who underwent reduction mammoplasty surgery at
Baystate Medical Center in Springfield, MA, USA, and banked at the Pioneer Valley Life Sciences Institute; Up, Upregulated.
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associations were not statistically significant. Overall, these
trends suggest that the parity signature remains weakly
expressed in the tissues of ER + breast cancer patients.
We also observed differences in parity associations by
ER status for SHL and UICH signatures (data not shown);
however, these associations were weaker than those for
the PVLSI signature.
We refined the parity signature by identifying 41 genes
consistently associated with parity across all three GSEA
analyses and significantly enriched for PVLSI signature
by parity status, that is, in cancer-adjacent normal tissue
overall and in ER + as well as ER + tumor tissue analyses
(see Table 5 and top 41 genes in Additional file 1: Table S3).
A pathway analysis based on these 41 genes revealed
the following top 10 biological processes: response towounding; leukocyte, cell, lymphocyte and T-cell activa-
tion; immune system process; cellular response to calcium
ion; and immune, inflammatory and defense responses.
Discussion
In this study, we identified a significant gene expression
signature that was upregulated in breast tissues of parous
compared to nulliparous healthy women. Similar to a pre-
viously published parity-related signature by Asztalos et al.
[24] (UICH), which was constructed by selecting genes
from the literature, our newly identified signature (selected
using an agnostic, supervised analysis) was enriched for
inflammation and immune response genes. Although re-
searchers have previously shown in animal studies that
upregulation of inflammatory response–related genes was
present in the early days of involution and diminished as
Table 3 Associations between parity in PVLSI and PBCS data sets and gene expression enrichmenta
PVLSI signature SHL signature UICH signature
PVLSI normal tissues
GSEA ESb 0.98 −0.52 0.71
GSEA FWERb 0% (sig) N/A 3% (sig)
Creighton analysisc Negative Positive Negative Positive Negative Positive
Nulliparous 37 (69%) 17 (31%) 22 (41%) 32 (59%) 33 (61%) 21 (39%)
Parous 27 (36%) 49 (64%) 45 (59%) 31 (41%) 30 (39%) 46 (61%)
OR (95% CI)d 3.95 (1.88 to 8.29) 0.47 (0.23 to 0.96) 2.4 (1.18 to 4.92)
P-valuee 0.0002 (sig) N/A 0.015 (sig)
PBCS cancer-adjacent normal tissues
GSEA ESb 0.52 0.24 0.60
GSEA FWERb 5% (sig) 37% 14% (sig)
Creighton analysisc Negative Positive Negative Positive Negative Positive
Nulliparous 17 (57%) 13 (43%) 16 (53%) 14 (47%) 15 (50%) 15 (50%)
Parous 58 (49%) 61 (51%) 62 (52%) 57 (48%) 62 (52%) 57 (48%)
OR (95% CI)d 1.38 (0.61 to 3.08) 1.05 (0.47 to 2.34) 0.92 (0.41 to 2.05)
P-valuee 0.44 0.90 0.84
PBCS tumor tissues
GSEA ESb 0.47 0.40 0.58
GSEA FWERb 18% 24% 21%
Creighton analysisc Negative Positive Negative Positive Negative Positive
Nulliparous 16 (53%) 14 (47%) 14 (47%) 16 (53%) 21 (70%) 9 (30%)
Parous 58 (49%) 61 (51%) 55 (46%) 64 (54%) 65 (55%) 54 (45%)
OR (95% CI)d 1.20 (0.54 to 2.68) 1.02 (0.56 to 2.27) 1.94 (0.82 to 4.58)
P-valuee 0.65 0.96 0.13
aCI, Confidence interval; ES, Enrichment score; FDR, False discovery rate; FWER, Family-wise error rate; GSEA, Gene set enrichment analysis; OR, Odds ratio; N/A,
Not applicable; PVLSI, Samples obtained from normal breast tissue of 130 women who underwent reduction mammoplasty surgery at Baystate Medical Center in
Springfield, MA, USA, and banked at the Pioneer Valley Life Sciences Institute; SHL, Normal breast samples from 107 postmenopausal healthy volunteers recruited
at the Sunderby Hospital in Luleå, Sweden; UICH, Mammoplasty benign biopsy specimens from 24 premenopausal women from the University of Illinois at Chicago
Hospital. bIn GSEA analysis, ES indicates the GSEA enrichment score and FWER is the corresponding family-wise error rate and considered significant (sig) if ≤ 15%. cIn
Creighton analysis, “Positive” and “Negative” indicate enriched and not enriched expression of parity signature, respectively. dIn Creighton analysis, odds ratios (ORs) and
95% confidence intervals (CIs) were obtained by unconditional logistic regression analysis with observed parity as the outcome variable and nulliparity as the reference.
eIn Creighton analysis, P-values were obtained by χ2 test or Fisher’s exact test if the expected cell count was less than five, and considered significant (sig) if ≤ 0.05.
Table 4 Associations between parity and gene expression enrichment of PVLSI parity signature in cancer-adjacent and
tumor tissues from PBCS patients by estrogen receptor tumor typea
Cancer-adjacent normal tissue, ER+ Tumor tissue, ER+ Cancer-adjacent normal tissue, ER− Tumor tissue, ER−
GSEA ESb 0.45 0.50 0.37 0.31
GSEA FWERb 12% (sig) 15% (sig) 21% 44%
Creighton analysisc Negative Positive Negative Positive Negative Positive Negative Positive
Nulliparous 16 (62%) 10 (38%) 15 (58%) 11 (42%) 1 (25%) 3 (75%) 1 (25%) 3 (75%)
Parous 46 (51%) 44 (49%) 50 (56%) 40 (44%) 12 (43%) 16 (57%) 8 (29%) 20 (71%)
OR (95% CI)d 1.53 (0.63 to 3.73) 1.91 (0.45 to 2.6) 0.44 (0.04 to 4.82) 0.83 (0.07 to 9.25)
P-valuee 0.35 0.85 0.63 1.00
aCI, 95% confidence interval; ER, Estrogen receptor; ES, Enrichment score; FWER, Family-wise error rate; GSEA, Gene set enrichment analysis; OR, Odds ratio; PBCS,
Polish Breast Cancer Case–Control Study; PVLSI, Samples obtained from normal breast tissue of 130 women who underwent reduction mammoplasty surgery at
Baystate Medical Center in Springfield, MA, USA, and banked at the Pioneer Valley Life Sciences Institute; sig, Significant. bIn GSEA analysis, ES indicates the GSEA
enrichment score and FWER the corresponding family-wise error rate, with results considered significant (sig) if ≤ 15%. cIn Creighton analysis, “Positive” and “Negative”
indicate enriched and nonenriched expression of parity signature. dIn Creighton analysis, odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by
unconditional logistic regression analysis with observed parity as the outcome variable and nulliparity as the reference. eIn Creighton analysis, P-values
were obtained by χ2 test or Fisher’s exact test if the expected cell count was less than five, and values were considered significant (sig) if ≤ 0.05.
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Table 5 Forty-one genes associated with parity across all three gene set enrichment analysesa
Gene symbol Gene name FCb P-valueb FDRb
CD163L1 Scavenger receptor cysteine-rich type 1 protein M160 1.50 0.00006 0
FCGR2A Fc fragment of IgG, low affinity IIa, receptor for (CD32) 1.61 0.00006 0
ALOX5AP Arachidonate 5-lipoxygenase-activating protein 1.52 0.00007 0
VNN1 Vanin 1 1.62 0.00007 0
CD33 CD33 antigen (gp67) 1.54 0.00007 0
CD28 CD28 antigen (Tp44) 1.84 0.00007 0
FCGR2B Fc fragment of IgG, low-affinity IIb, receptor for (CD32) 1.92 0.00009 0
EAF2 ELL-associated factor 2 1.27 0.00009 0
LCP2 Lymphocyte cytosolic protein 2 1.25 0.00011 0
IL10RA Interleukin 10 receptor, α 1.32 0.00011 0
BLNK B-cell linker 1.34 0.00012 0
SAMSN1 SAM domain, SH3 domain and nuclear localization, 1 1.43 0.00013 0
CYB5R4 NADPH cytochrome B5 oxidoreductase 1.33 0.00017 0
HTR2B 5-hydroxytryptamine (serotonin) receptor 2B 1.69 0.00031 0
TTC7A Tetratricopeptide repeat domain 7A 1.17 0.00032 0
ATP6V1F ATPase, H + transporting, lysosomal 14 kDa, V1 subunit F 1.20 0.00034 0
TLR7 Toll-like receptor 7 1.28 0.00037 0
ANKRD27 Ankyrin repeat domain 27 (VPS9 domain) 1.19 0.00041 0
ITGAM Integrin, α M 1.55 0.00044 0
CCDC109B Hypothetical protein FLJ20647 1.27 0.00045 0
CPVL Carboxypeptidase, vitellogenic-like 1.48 0.00048 0
LEPROTL1 Leptin receptor overlapping transcript-like 1 1.19 0.00062 0.003
CCR1 Chemokine (C-C motif) receptor 1 1.30 0.00068 0.004
S100A10 S100 calcium binding protein A10 1.45 0.00073 0.004
ALG14 Hypothetical protein MGC19780 1.26 0.00093 0.004
SLC7A7 Solute carrier family 7, member 7 1.30 0.00093 0.004
CHRDL1 Chordin-like 1 1.52 0.00095 0.004
S100A4 S100 calcium binding protein A4 1.40 0.00098 0.004
ITGAE Integrin α E 1.27 0.00098 0.004
CCL2 Chemokine (C-C motif) ligand 2 1.51 0.00102 0.004
CYP4X1 Cytochrome P450, family 4, subfamily X, polypeptide 1 1.49 0.00128 0.004
CCNDBP1 Cyclin D-type binding-protein 1 1.18 0.00144 0.006
TNFSF13B Tumor necrosis factor (ligand) superfamily, member 13b 1.30 0.00148 0.006
BLVRA Biliverdin reductase A 1.24 0.00163 0.006
C8orf40 Hypothetical protein BC013035 1.15 0.00174 0.006
BIN2 Bridging integrator 2 1.20 0.00185 0.006
CD48 CD48 antigen (B-cell membrane protein) 1.26 0.00188 0.006
TSG101 Tumor susceptibility gene 101 1.13 0.00199 0.006
GLRX Glutaredoxin (thioltransferase) 1.40 0.00200 0.006
B3GALT4 β 1,3-galactosyltransferase, polypeptide 4 1.25 0.00206 0.006
aFC, Fold change; FDR, False discovery rate; IgG, Immunoglobulin G; PVLSI, Samples obtained from normal breast tissue of 130 women who underwent reduction
mammoplasty surgery at Baystate Medical Center in Springfield, MA, USA, and banked at the Pioneer Valley Life Sciences Institute; SAM, Sterile α domain. bFold
change (FC), P-value and false discovery rate (FDR) are derived from gene expression comparison of cancer-free parous versus nulliparous PVLSI women. Genes
shown were significantly enriched for PVLSI signature by parity status, that is, in analyses of cancer-adjacent normal tissue overall and estrogen receptor–positive
and estrogen receptor–positive tumor tissues.
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http://breast-cancer-research.com/content/16/4/R74involution progressed [38-40], our findings suggest that
pregnancy has a lasting effect that can be detected many
years after completion of a pregnancy. In contrast, the SHL
study investigators did not show an increase in immune
activity in postmenopausal women and concluded that the
upregulation of inflammation and immune response–
related genes persists during postpartum involution but
wanes after menopause [12]. However, the subjects in the
SHL study were much older (mean age = 60 years) than
the PVLSI and UICH patients (mean ages = 37 and 29
years, respectively).
We tested three parity-related signatures in genome-
wide expression profiling data sets derived from paired
tumor-adjacent normal and breast tumor tissues collected
from breast cancer cases. We found that parity-related
gene signatures were preserved in adjacent normal and
tumor tissues, but only among patients with ER + tumors.
This is interesting in light of our recent findings suggestive
of immune response signatures being dysregulated in
normal tissue adjacent to triple-negative breast cancers
(P Casbas-Hernandez et al., unpublished data). It is pos-
sible that some of the inflammatory genes altered by
parity are also responsive to the development of ER −
breast cancer and, therefore, that parity-associated signa-
tures become disrupted with progression of ER − disease.
The results of our previous work suggest that cancer-
adjacent microenvironments show altered expression of
wound response genes [27]. ER−, and especially triple-
negative, breast cancers may be particularly prone to up-
regulated cytokines or inflammatory responses, which
may lead to the disruption of the parity-associated proin-
flammatory pathways in ER − breast cancers. However, it
is important to note that cytokines that are traditionally
associated with inflammation may also play a regulatory
role in breast tissue without inducing an immune re-
sponse [41]. In the absence of direct evidence of inflam-
matory infiltrates, the inflammation signatures must be
interpreted as a change in microenvironment without spe-
cifying particular immune suppression or immune avoid-
ance mechanisms. Alternatively, differential expression of
parity-associated signatures in ER + versus ER − disease
may reflect the differential effect of parity on ER + versus
ER − tumors. It appears that, in any case, pregnancy is as-
sociated with persistent changes in gene expression that
are preserved in women with ER + breast cancer. In a re-
cent study, researchers found that parity decreased the
number of hormone receptor–positive luminal cells but
had no effect on the basal stem and/or progenitor cells
[42]. This suggests that parity may act differently on cells
that become luminal versus basal-like breast cancers. If
the parity signature is expressed predominantly in normal
breast luminal epithelium, then it may be expected that
the signature will be expressed only in luminal tumors. Al-
ternatively, the proinflammatory signaling that has beenassociated with a basal-like stromal response [43] may ob-
scure or disrupt the cytokine expression induced by parity.
Identifying the differential effects of parity on distinct cell
populations and showing their relevance in human tissues
is important for identifying targetable pathways in cancer
prevention.
The variations we observed in the expression of the par-
ity signature by ER status are unlikely to have been driven
by age, age at first birth or years since most recent birth,
because these variables had similar distributions in the
ER + and ER − cases evaluated. In addition, the RM-
derived parity signature was not significantly associated
with tumor characteristics (tumor size, histology, differen-
tiation or lymph node positivity), nor was it associated
with overall survival in Kaplan-Meier analyses (data not
shown). These data suggest that the signature reflects par-
ity status in ER + breast cancer cases and not a tendency
for parous women to have a different prevalence of a par-
ticular subtype of breast cancer. However, the weaker as-
sociation between the gene signature and parity in tumors
(relative to normal) is suggestive of the fact that, as tumors
progress, they devolve to more unstable states which no
longer accurately reflect exposure history.
Comparison of signatures across data sets is challenging
because of the differences in profiling platforms, methods
of gene selection, patient characteristics (for example, age
and body mass index (BMI)) and sample procurement
procedures in different studies. Consistent with this, we
found limited concordance in parity-related gene content
results across different signatures. Some of the previously
published signatures [12] were obtained primarily in mi-
crodissected epithelium, whereas our novel signature was
obtained from the analysis of RM breast tissues that con-
sisted of both epithelium and stroma. The discrepancies
in gene signatures emphasize the challenges of obtaining a
consistent parity signature with tissues that differ in com-
position. Our findings add new knowledge about how such
signatures persist across the diversity of cell types in breast
tissue, an understudied field. Stromal cells predominate in
noninvolved, tumor-adjacent tissues, and stromal responses
are important to understanding the selective pressures
faced by tumors evolving from surrounding stroma [44-47].
In spite of these differences, several signatures showed
consistent associations across data sets. Further, some
genes were common across signatures. ESR2 was identi-
fied as one of the top significantly upregulated genes in
parous women in both the PVLSI and UICH studies.
ESR2 is an ER isoform that has been shown to oppose the
proliferative effect of ESR1 [48]. Increased expression of
ESR2 following pregnancy may reduce the proliferation of
breast epithelial cells. Interestingly, in the SHL study, the
researchers identified other genes in the ER signaling
pathway that were upregulated in parous women, such as
GATA3. GATA3 is a transcription factor that regulates
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gland and whose expression is highly associated with ER.
Together with the finding of ESR2 upregulation in the
PVLSI and UICH studies, these data suggest that genes
involved in the ER-regulated pathways could be under
permanent transcriptional modification as a manifest-
ation of a higher degree of parity-associated cell differenti-
ation. In addition, consistent with the SHL study, our
parity signature also consisted of upregulated genes. One
gene in common between the SHL and PVLSI signatures
was TRAF3-interacting, c-Jun N-terminal kinase–activat-
ing modulator (TRAF3IP3). Genes involved in cell adhe-
sion and differentiation of leukocytes were found to be
enriched in both signatures.
Overall, the separation of gene expression by parity status
in our data derived from RM patients was not as strong as
for other risk factors such as obesity [26], with expression
of the signature not found to be in the expected direction
in some parous women. This may suggest heterogeneity
among patients or the effects of parity on the breast micro-
environment being transient. However, other recent find-
ings suggest that parity may alter the composition of
breast tissue, notably shifting the tissue composition to-
ward greater adiposity, and these effects may be persistent
(X Sun et al., unpublished data). Thus, the persistent
inflammatory effects observed in our data may reflect a
smoldering inflammatory reaction or a long-lasting shift in
stromal composition rather than an acute reaction observed
during postlactation involution [5,49]. We cannot exclude
some confounding by BMI or age in these analyses, because
(1) BMI information was available for only half of the RM
patients and (2) most parous women in this data set were
also older. Nevertheless, the BMI distributions (mean ±
standard deviation (SD)) in parous women (mean = 31,
SD = 6) and nulliparous women (mean = 30, SD = 6) were
very similar. In addition, BMI is only modestly increased
with parity [50], and more substantial changes with BMI
are associated with age [51]. We verified that the large ma-
jority of the identified parity genes were not part of the age-
or BMI-related signature identified in the same population
[26,52]. Other variables, such as age at first birth and years
since most recent birth, may affect gene expression pat-
terns. However, our present study is not powered to ad-
dress these questions. None of the subgroup analyses we
conducted yielded significant results (FWER > 15%), but fu-
ture studies addressing these relationships and adequately
powered for subanalyses of how plausible confounders (in-
cluding age, BMI, lactation, number of children, age at first
birth and years since most recent birth) influence gene ex-
pression–parity associations will be helpful.
Conclusions
The strength of our study includes the identification of a
novel, parity-related signature in stroma-rich breast tissuefrom healthy women and comparisons with different parity
signatures. We tested multiple signatures in both cancer-
adjacent and tumor tissues in the same set of breast cancer
patients derived from a population-based study to assess
whether parity-related signatures were related to tumor
progression and subtype heterogeneity. However, our study
also has limitations. The small sample size in the training
(PVLSI) and test (PBCS) sets prohibited analyses match-
ing on important confounders such as age and BMI or on
finer subtypes such as triple-negative or basal-like tumors.
In addition, the variation in study subjects, tissues and
methods across studies posed challenges to reproducing
parity signatures across data sets. Despite these limitations,
we found that inflammatory and immune responses and
ER regulatory pathways were commonly associated with
parity in multiple data sets. Furthermore, parity-related
molecular changes appeared to be preserved in breast can-
cer patients with ER + tumors but disrupted in patients
with ER − tumors, which may at least partially account for
the observed differential effect that parity has on these two
tumor subtypes.
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